In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Delaware's Supreme Court sides with drugmakers including GSK (GSK) and Pfizer (PFE), rejecting expert testimony linking ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

GSK Plc will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its reflux medication Zantac was contaminated with a suspected carcinogen. (Chris Walker ...

GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac ...

GSK to settle 80,000 Zantac cases for up to $2.2 billion Plaintiffs argued the company knew Zantac's active ingredient, ranitidine, turned into a potential carcinogen under certain conditions.

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen. The ...